Latest Articles
Acupuncture Increases IVF Success - HealthCMi
Acupuncture Increases IVF Success HealthCMi
Published: April 26, 2024, 7 a.m.
Tiffany Haddish Opens Up About 8 'Devastating' Miscarriages Amid Endometriosis Battle - Women's Health
Tiffany Haddish Opens Up About 8 'Devastating' Miscarriages Amid Endometriosis Battle Women's Health
Published: April 25, 2024, 7 a.m.
Tiffany Haddish Says She's Been Diagnosed With Endometriosis and Has Experienced 8 Miscarriages - Marie Claire
Tiffany Haddish Says She's Been Diagnosed With Endometriosis and Has Experienced 8 Miscarriages Marie Claire
Published: April 25, 2024, 7 a.m.
Tiffany Haddish reveals she has suffered eight 'devastating' miscarriages amid painful endometriosis battle - Daily Mail
Tiffany Haddish reveals she has suffered eight 'devastating' miscarriages amid painful endometriosis battle Daily Mail
Published: April 25, 2024, 7 a.m.
Tiffany Haddish Reveals She's Suffered 8 Miscarriages Due To Endometriosis, The Latest Being Last Year: 'It's So F*cking Devastating' - TheJasmineBrand
Tiffany Haddish Reveals She's Suffered 8 Miscarriages Due To Endometriosis, The Latest Being Last Year: 'It's So F*cking Devastating' TheJasmineBrand
Published: April 25, 2024, 7 a.m.
Research progress in endometriosis-associated ovarian cancer - Frontiers
Research progress in endometriosis-associated ovarian cancer Frontiers
Published: April 24, 2024, 7 a.m.
Endometriosis: ‘I was feeling like a burden, feeling like it was all in my head’ - BBC
Endometriosis: ‘I was feeling like a burden, feeling like it was all in my head’ BBC
Published: April 24, 2024, 7 a.m.
GSK's endometrial cancer drug receives FDA approval - ShareCast
GSK's endometrial cancer drug receives FDA approval ShareCast
Published: April 24, 2024, 7 a.m.
Education Session to Discuss the Implementation of New Drugs in Gynecologic Oncology - ASCO Daily News
Education Session to Discuss the Implementation of New Drugs in Gynecologic Oncology ASCO Daily News
Published: April 24, 2024, 7 a.m.
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses - Nature.com
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses Nature.com
Published: April 23, 2024, 7 a.m.
Link copied to clipboard!